Home  |  Contact

Cellosaurus CHP-134 (CVCL_1124)

[Text version]

Cell line name CHP-134
Synonyms CHP 134; CHP_134; CHP134; Children's Hospital of Philadelphia-134
Accession CVCL_1124
Resource Identification Initiative To cite this cell line use: CHP-134 (RRID:CVCL_1124)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Doubling time: 57.6 hours (PubMed=10079); ~30 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North0.15
East Asian, South0
South Asian0.93
European, North70.26
European, South28.62
Disease Adrenal gland neuroblastoma (NCIt: C4827)
Neuroblastoma (ORDO: Orphanet_635)
Derived from metastatic site: Adrenal gland.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 1Y1M
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DepMap; DSMZ; ECACC; RCB

CSF1PO9,12 (Cosmic-CLP; RCB)
9,13 (DepMap; DSMZ; ECACC)
D8S11798,14 (DepMap)
14 (DSMZ)
D13S3178,10,11 (DepMap)
8,11 (Cosmic-CLP; DSMZ; ECACC; RCB)
D16S53911 (RCB)
11,13 (Cosmic-CLP; DepMap; DSMZ; ECACC)
Penta D9
Penta E5,7

Run an STR similarity search on this cell line

Schlesinger H.R., Gerson J.M., Moorhead P.S., Maguire H., Hummeler K.
Establishment and characterization of human neuroblastoma cell lines.
Cancer Res. 36:3094-3100(1976)

PubMed=7139592; DOI=10.1016/0165-4608(82)90105-4
Gilbert F., Balaban G.B., Moorhead P.S., Bianchi D., Schlesinger H.R.
Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.
Cancer Genet. Cytogenet. 7:33-42(1982)

PubMed=6888561; DOI=10.1038/305245a0
Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.
Nature 305:245-248(1983)

Thiele C.J.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)

PubMed=18724359; DOI=10.1038/nature07261
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=18923524; DOI=10.1038/nature07399
Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S.
Oncogenic mutations of ALK kinase in neuroblastoma.
Nature 455:971-974(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=23202128; DOI=10.1038/ng.2493
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013)

PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cell line collections DSMZ; ACC-653
ECACC; 06122002
RCB; RCB0487
Cell line databases/resources CLO; CLO_0051417
Cell_Model_Passport; SIDM00285
CGH-DB; 75-1
CGH-DB; 9099-4
Cosmic-CLP; 910941
DepMap; ACH-001338
DSMZCellDive; ACC-653
Anatomy/cell type resources BTO; BTO:0002989
Biological sample resources BioSample; SAMN03472330
BioSample; SAMN03473466
Chemistry resources ChEMBL-Cells; CHEMBL3308253
ChEMBL-Targets; CHEMBL2366128
GDSC; 910941
PharmacoDB; CHP134_199_2019
Encyclopedic resources Wikidata; Q54813265
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM313800
GEO; GSM333795
GEO; GSM563356
GEO; GSM692863
GEO; GSM1366404
GEO; GSM1669677
GEO; GSM2371222
GEO; GSM2394376
GEO; GSM3145699
Polymorphism and mutation databases Cosmic; 688063
Cosmic; 801744
Cosmic; 848934
Cosmic; 910941
Cosmic; 920253
Cosmic; 930063
Cosmic; 947707
Cosmic; 1019934
Cosmic; 1037353
Cosmic; 1099150
Cosmic; 1109362
Cosmic; 1153779
Cosmic; 1161986
Cosmic; 1526620
Cosmic; 2131592
Cosmic; 2393629
Cosmic; 2485943
IARC_TP53; 21226
Progenetix; CVCL_1124
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update23-Jun-2022
Version number32